Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Avricore Health (8VP1) Stock Price & Analysis

0 Followers

8VP1 Stock Chart & Stats

€0.02€0.00(0.00%)
At close: 5:30 PM GMT+1
€0.03€0.035€0.04€0.045Sep 4Sep 17Sep 22Sep 30
Day’s Range
EUR 0.02 - EUR 0.02
52-Week Range
EUR 0.02 - EUR 0.05
Previous Close
EUR 0.02
Volume
N/A
Average Volume (3M)
845
Market Cap
EUR 3.60M
Enterprise Value
EUR 5.89M
Total Cash (Recent Filing)
EUR 922.55K
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
0.26
Next Earnings
Nov 26, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

Essentially no debt gives Avricore greater financial flexibility than a leveraged peer during operating stress. The absence of refinancing obligations and interest expense reduces fixed claims on cash, although this benefit depends on the company improving profitability and avoiding prolonged cash consumption.

Historical Gross Profit Capability

Positive gross profit and improved margins in 2023–2024 show that Avricore has previously demonstrated some ability to monetize its operations above direct costs. Re-establishing that performance would provide a foundation for operating leverage, reinvestment, and more durable earnings quality.

Prior Operating Cash Generation

Positive operating cash flow in 2023 and especially 2024 indicates the business has previously converted operations into cash rather than relying exclusively on external funding. That history is a constructive capability, though it must recur consistently to offset the latest deterioration.

Bears Say

Severe Revenue Deterioration

The sharp revenue decline after stronger 2023–2024 levels weakens visibility into the scale and stability of Avricore’s business. A persistently depressed revenue base can reduce operating leverage, limit investment capacity, and make recovery dependent on successfully rebuilding demand and execution.

Negative Profitability

Negative TTM gross profit and widening net losses indicate that current revenue is not covering the economics of the business. Continued losses can constrain reinvestment, weaken shareholder returns, and increase the difficulty of demonstrating a sustainable path to profitability over the next several quarters.

Recent Cash Burn

Negative operating and free cash flow in the latest periods means Avricore is currently consuming cash while its operations remain unprofitable. If this pattern persists, funding needs could increase and management may have less flexibility to support platform development or absorb further operating weakness.

Avricore Health News

8VP1 FAQ

What was Avricore Health’s price range in the past 12 months?
Avricore Health lowest stock price was €0.02 and its highest was €0.05 in the past 12 months.
What is Avricore Health’s market cap?
Avricore Health’s market cap is €3.60M.
When is Avricore Health’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Avricore Health’s earnings last quarter?
Avricore Health released its earnings results on Sep 01, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Avricore Health overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Avricore Health pay dividends?
Avricore Health does not currently pay dividends.
What is Avricore Health’s EPS estimate?
Avricore Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avricore Health have?
Avricore Health has 126,369,670 shares outstanding.
What happened to Avricore Health’s price movement after its last earnings report?
Avricore Health reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went down -32%.
Which hedge fund is a major shareholder of Avricore Health?
Currently, no hedge funds are holding shares in DE:8VP1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology